Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for Graves' Ophthalmopathy
NCT00595335Phase 3Completed
- Start
- Apr 2008
- Primary completion
- Mar 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in Graves' ophthalmopathy (TED). Started Apr 2008; status: completed.
02
Drugs
rituximab
03
Conditions
Graves' ophthalmopathy (TED)
Beyond the preview
Go deeper on NCT00595335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00595335.